Follistatins, activins and inhibins during osteoporosis therapy with denosumab or zoledronate and after their discontinuation

被引:0
作者
Anastasilakis, Athanasios D. [1 ]
Makras, Polyzois [2 ,3 ]
Polyzos, Stergios A. [4 ]
Kumar, Ajay [5 ]
Kalra, Bhanu [5 ]
Mantzoros, Christos S. [6 ,7 ]
机构
[1] 424 Gen Mil Hosp, Dept Endocrinol, Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece
[2] 251 Hellen Air Force & VA Gen Hosp, Dept Endocrinol & Diabet, Athens, Greece
[3] 251 Hellen Air Force & VA Gen Hosp, Dept Med Res, Athens, Greece
[4] Aristotle Univ Thessaloniki, Med Sch, Lab Pharmacol 1, Thessaloniki, Greece
[5] Ansh Labs, Webster, TX USA
[6] Harvard Med Sch, Boston VA Healthcare Syst, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
[7] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
关键词
activin; denosumab; discontinuation; follistatin; osteoporosis; zoledronate;
D O I
10.1111/dom.16208
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:2288 / 2293
页数:6
相关论文
共 9 条
[1]   The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis [J].
Anastasilakis, Athanasios D. ;
Polyzos, Stergios A. ;
Makras, Polyzois ;
Savvidis, Matthaios ;
Mantzoros, Christos S. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (09) :1306-1314
[2]   Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study [J].
Anastasilakis, Athanasios D. ;
Polyzos, Stergios A. ;
Savvidis, Matthaios ;
Anastasilakis, Dimitrios A. ;
Sarridimitriou, Athanasios ;
Kumar, Ajay ;
Kalra, Bhanu ;
Makras, Polyzois ;
Mantzoros, Christos S. .
ENDOCRINE, 2023, 81 (03) :573-578
[3]   Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study☆ [J].
Anastasilakis, Athanasios D. ;
Polyzos, Stergios A. ;
Rodopaios, Nikolaos E. ;
Makras, Polyzois ;
Kumar, Ajay ;
Kalra, Bhanu ;
Mantzoros, Christos S. .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 141
[4]   Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review [J].
Anastasilakis, Athanasios D. ;
Makras, Polyzois ;
Yavropoulou, Maria P. ;
Tabacco, Gaia ;
Naciu, Anda Mihaela ;
Palermo, Andrea .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (01) :1-28
[5]   Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial [J].
Anastasilakis, Athanasios D. ;
Papapoulos, Socrates E. ;
Polyzos, Stergios A. ;
Appelman-Dijkstra, Natasha M. ;
Makras, Polyzois .
JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (12) :2220-2228
[6]   Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis [J].
Anastasilakis, Athanasios D. ;
Polyzos, Stergios A. ;
Makras, Polyzois .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 179 (01) :R31-R45
[7]   Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice [J].
Brent, Mikkel Bo ;
Lodberg, Andreas ;
Bromer, Frederik Duch ;
van der Eerden, Bram C. J. ;
Eijken, Marco ;
Bruel, Annemarie ;
Thomsen, Jesper Skovhus .
BONE, 2021, 142
[8]   Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin [J].
Gilson, Helene ;
Schakman, Olivier ;
Kalista, Stephanie ;
Lause, Pascale ;
Tsuchida, Kunihiro ;
Thissen, Jean-Paul .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2009, 297 (01) :E157-E164
[9]   A soluble activin type IIA receptor induces bone formation and improves skeletal integrity [J].
Pearsall, R. Scott ;
Canalis, Ernesto ;
Cornwall-Brady, Milton ;
Underwood, Kathryn W. ;
Haigis, Brendan ;
Ucran, Jeffrey ;
Kumar, Ravindra ;
Pobre, Eileen ;
Grinberg, Asya ;
Werner, Eric D. ;
Glatt, Vaida ;
Stadmeyer, Lisa ;
Smith, Deanna ;
Seehra, Jasbir ;
Bouxsein, Mary L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (19) :7082-7087